Erythropoietin-induced, antibody-mediated pure red cell aplasia

European Journal of Clinical Investigation, Supplement

Volumn 35, Issue 3, 2005, Pages 95-99

  Rossert, Jérôme ^a   Maroni, Brad ^b   Aljama, Pedro ^b   Casadevall, Nicole ^b   Cooper, Max ^b   Delage, Robert ^b   Eckardt, Kai Uwe ^b   De Francisco, Angel Martin Luis ^b   Hörl, Walter ^b   Jelkmann, Wolfgang ^b   Johnson, David ^b   Locatelli, Francesco ^b   Macdougall, Iain ^b   Nissenson, Allen R ^b   Pollock, Carol ^b   Schellekens, Huub ^b   Thorpe, Robin ^b   Toffelmire, Edwin ^b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b NONE

Author keywords

Anaemia; Aplasia; Diagnosis; Epoetin; Immunogenicity; Therapy

Indexed keywords

CD20 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ERYTHROPOIETIN; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; AUTOIMMUNE DISEASE; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CELL MATURATION; ERYTHROID PRECURSOR CELL; HEMATOLOGIC DISEASE; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; PLASMAPHERESIS; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RETROSPECTIVE STUDY; REVIEW;

ANTIBODIES; BLOOD CELL COUNT; EPOETIN ALFA; ERYTHROCYTES; ERYTHROPOIETIN; HEMATINICS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RED-CELL APLASIA, PURE;

EID: 28944443558     PISSN: 0960135X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Dessypris EN. The biology of pure red cell aplasia. Semin Hematol 1991;28:275-84.
2. Kondo H, Mori A, Watanabe J, Takada J, Takahashi Y, Iwasaki H. Pure red cell aplasia associated with parvovirus B19 infection in T-large granular lymphocyte leukemia. Leuk Lymphoma 2001;42:1439-43.
3. Lacombe C, Casadevall N, Muller O, Varet B. Erythroid progenitors in adult chronic pure red cell aplasia: relationship of in vitro erythroid colonies to therapeutic response. Blood 1984;64:71-7.
4. Handa SI, Schofield KP, Sivakumaran M, Short M, Pumphrey RS. Pure red cell aplasia associated with malignant thymoma, myasthenia gravis, polyclonal large granular lymphocytosis and clonal thymicT cell expansion. J Clin Pathol 1994;47:676-9.
5. Dessypris EN, Fogo A, Russell M, Engel E, Krantz SB. Studies on pure red cell aplasia. X. Association with acute leukemia and significance of bone marrow karyotype abnormalities. Blood 1980;56:421-6.
6. Dessypris EN, McKee CL Jr, Metzantonakis C, Teliacos M, Krantz SB. Red cell aplasia and chronic granulocytic leukaemia. Br J Haematol 1981;48:217-25.
7. Linardaki GD, Boki KA, Fertakis A, Tzioufas AG. Pure red cell aplasia as presentation of systemic lupus erythematosus: antibodies to erythropoietin. Scand J Rheumatol 1999;28:189-91.
8. Dessypris EN, Redline S, Harris JW, Krantz SB. Diphenylhydantoin-induced pure red cell aplasia. Blood 1985;65:789-94.
9. Thompson DF, Gales MA. Drug-induced pure red cell aplasia. Pharmacotherapy 1996;16:1002-8.
10. Marmont A, Peschle C, Sanguineti M, Condorelli M. Pure red cell aplasia (PRCA): response of three patients of cyclophosphamide and/or antilymphocyte globulin (ALG) and demonstration of two types of serum IgG inhibitors to erythropoiesis. Blood 1975;45:247-61.
11. Peschle C, Marmont AM, Marone G, Genovese A, Sasso GF, Condorelli M. Pure red cell aplasia: studies on an IgG serum inhibitor neutralizing erythropoietin. Br J Haematol 1975;30:411-7.
12. Dessypris EN, Baer MR, Sergent JS, Krantz SB. Rheumatoid arthritis and pure red cell aplasia. Ann Intern Med 1984;100:202-6.
13. Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996;334:630-3.
14. Bergrem H, Danielson BG, Eckardt KU, Kurtz A, Stridsberg M. A case of antierythropoietin antibodies following recombinant human erythropoietin treatment. In: Bauer C, Koch KM, Sciqalla P, Wieczorek L, eds. Erythropoietin: molecular physiology and clinical application. New York, NY: Marcel Dekker;1993.pp. 265-75.
15. Peces R, de la Torre M, Alcazar R, Urra JM. Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 1996;335:523-4.
16. Prabhakar SS, Muhlfelder T. Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 1997;47:331-5.
17. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75.
18. Casadevall N. Antibodies against rHuEPO: native and recombinant. Nephrol Dial Transplant 2002;17 (Suppl. 5):42-7.
19. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU et al. Erythropoiesis stimulating agents and antibody-mediated pure red cell aplasia: where are we now and where do we go from here? Nephrol Dial Transplant 2003;2004;19:288-93.
20. Medicines CotSo. Sourcing of plasma and urinary derived medicinal products. Available at: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/ safetymessages/plasma14303.pdf. Accessed 20 February 2003.
21. Janssen-Cilag. Letter. Eprex® (Epoetin alfa) erythroblastopenia (pure red cell aplasia or PRCA). Update of information. Accessed 31 March 2002.
22. Johnson & Johnson Pharmaceutical Research & Development LLC. Summary of PRCA case reports. Available at: http://www.jnj.com/news/jnj_news/ 1021024_095632.htm. Accessed 10 October 2003.
23. Swissmedic. Swissmedic medical update letter. Available at: http://www.swissmedic.ch/en/laien/overall.asp?lang=2&theme=0.00062.00004. 00001&theme_id =810&news_id=2588&page=1. Accessed 26 March 2003.
24. Kruger A, Schroer W, Rohrs F, Vescio G. PRCA in a patient treated with epoetin beta. Nephrol Dial Transplant 2003;18:1033-4.
25. Amgen Inc. Amgen statement on pure red cell aplasia. Available at: www.amgen.com/clinicians/prca.html. Accessed 29 August 2003.
26. Breckenridge A. Eprex (epoetin alfa) and pure red cell aplasia - Contraindication of subcutaneous administration to patients with chronic renal disease. Committee on Safety of Medicines. Available at: http://www.info.doh. gov.uk/doh/EmBroadcast.nsf/0/35595645f6304bfa80256c8d00456dcd?OpenDocument. Accessed 14 May 2003.
27. Donovan A. EPREX* (epoetin alfa) - Pure red cell aplasia (PRCA, erythroblastopenia). Amended advice on route of administration & reminder about storage conditions: Ortho Biotech; 17 July 2002.
28. ADRAC. Epoetin alfa and pure red cell aplasia. Available at: http://www.health.gov.au/tga/adr/aadrb/aadr0208.htm#4. Accessed 23 October 2003.
29. Weber G, Gross J, Kromminga A, Loew HH, Eckardt KU. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol 2002;13:2381-3.
30. Eckardt KU, Casadevall N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant 2003;18:865-9.
31. Egrie JC, Cotes PM, Lane J, Gaines Das RE, Tam RC. Development of radioimmunoassays for human erythropoietin using recombinant erythropoietin as tracer and immunogen. J Immunol Methods 1987;99:235-41.
32. Urra JM, de la Torre M, Alcazar R, Peces R. Rapid method for detection of anti-recombinant human erythropoietin antibodies as a new form of erythropoietin resistance. Clin Chem 1997;43:848-9.
33. Castelli G, Famularo A, Semino C, Machi AM, Ceci A, Cannella G et al. Detection of anti-erythropoietin antibodies in haemodialysis patients treated with recombinant human-erythropoietin. Pharmacol Res 2000;41:313-8.
34. Hoesel W, Gross J, Moller R, Kanne B, Wessner A, Muller G, Muller A, Gramaica-Ihle E, Fromme M, Bischoff S, Haselbeck A. Development and evaluation of a new ELISA for the detection and quantification of antierythropoietin antibodies in human sera. J Immunol Methods 2004;294:101-10.
35. Swanson SJ, Ferbas J, Mayeux P, Casadevall N. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract 2004;96:c88-95.
36. Zaentz SD, Krantz SB, Brown EB. Studies on pure red cell aplasia. Maintenance therapy with immunosuppressive drugs. Br J Haematol 1976;32:47-54.
37. Means RT Jr, Dessypris EN, Krantz SB. Treatment of refractory pure red cell aplasia with cyclosporine A: disappearance of IgG inhibitor associated with clinical response. Br J Haematol 1991;78:114-9.
38. Chng WJ, Tan LK, Liu TC. Cyclosporine treatment for patients with CRF who developed pure red blood cell aplasia following EPO therapy. Am J Kidney Dis 2003;41:692-5.
39. Panchapakesan U, Austin SK, Shafransky A, Lawrence JA, Savdie E. Recovery of pure red-cell aplasia secondary to antierythropoietin antibodies after cessation of recombinant human erythropoietin. Intern Med J 2003;33:468-71.
40. Verhelst D, Rossert J, Casadevall N, Kruger A, Eckardt K-U, Macdougall IC. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet 2004;363:1768-71.